The modulation of complement functional efficiency by serum histidine-rich glycoprotein (HRG) was investigated. Addition of exogenous HRG to prewarmed diluted serum, followed immediately by sensitized sheep erythrocytes (EA), resulted in enhanced hemolysis. However, when HRG was incubated with diluted serum for 10 minutes at 37"C, inhibition of hemolysis occurred. The biphasic modulation of complement function was also obtained with the complement alternative pathway when HRG was added to diluted serum for hemolysis of rabbit erythrocytes. Partial reduction of complement functional activity was shown when serum was absorbed by an HRG-Sepharose 6MB column. Western blot analysis showed that complement C8, C9, factor D, and S-protein in diluted serum were bound by nylon membraneimmobilized HRG. However, by immunoprecipitation of relatively undiluted serum with anti-HRG IgG beads, HRG was found to coprecipitate with S-protein and plasminogen, which suggested that HRG may complex with these proteins ISTIDINE-RICH glycoprotein (HRG) is a plasma H protein with an unusually high content of histidine and proline.' In vitro studies indicate that HRG is capable of binding to divalent cations: thrombospondin: and the lysine binding site of plasminogen.6 Although the physiologic function of HRG has not been well established, elevation of HRG level in plasma was reported to be associated with thr~mbophilia.~ Plasma HRG was shown to be elevated or decreased in cases of mild, moderate, or severe liver cirrhosis.8 HRG is also a negative acute-phase reactant, in that during the acute phase response there is a decreased HRG concentration in plasma that is inversely correlated with increased quantities of acute-phase proteins, such as C-reactive protein? The functional significance of these findings is not well defined.
The modulation of complement functional efficiency by serum histidine-rich glycoprotein (HRG) was investigated. Addition of exogenous HRG to prewarmed diluted serum, followed immediately by sensitized sheep erythrocytes (EA), resulted in enhanced hemolysis. However, when HRG was incubated with diluted serum for 10 minutes at 37"C, inhibition of hemolysis occurred. The biphasic modulation of complement function was also obtained with the complement alternative pathway when HRG was added to diluted serum for hemolysis of rabbit erythrocytes. Partial reduction of complement functional activity was shown when serum was absorbed by an HRG-Sepharose 6MB column. Western blot analysis showed that complement C8, C9, factor D, and S-protein in diluted serum were bound by nylon membraneimmobilized HRG. However, by immunoprecipitation of relatively undiluted serum with anti-HRG IgG beads, HRG was found to coprecipitate with S-protein and plasminogen, which suggested that HRG may complex with these proteins
ISTIDINE-RICH glycoprotein (HRG) is a plasma
H protein with an unusually high content of histidine and proline.' In vitro studies indicate that HRG is capable of binding to divalent cations: thrombospondin: and the lysine binding site of plasminogen. 6 Although the physiologic function of HRG has not been well established, elevation of HRG level in plasma was reported to be associated with thr~mbophilia.~ Plasma HRG was shown to be elevated or decreased in cases of mild, moderate, or severe liver cirrhosis.8 HRG is also a negative acute-phase reactant, in that during the acute phase response there is a decreased HRG concentration in plasma that is inversely correlated with increased quantities of acute-phase proteins, such as C-reactive protein? The functional significance of these findings is not well defined.
Modulation of immune cell function by HRG has been documented. HRG inhibits autorosette formation between murine T lymphocytes and autologous erythrocytes.lo-l2 HRG binds to a 56-Kd protein on the T-cell ~urface,'~ which results in suppression of T-cell proliferation when triggering T cells with interleukin-2 (IL-2) and antibodies against antigen receptor (CD23).14 HRG also participates in the inhibition of specific binding of heparin to the monocytic U937 cell line. 15 Our recent studies showed that HRG biphasically modulated macrophage Fc receptor (FcR) expression and FcR-dependent phagocytic functions, by either enhancing or reducing these functions in both a time-and dose-dependent manner. 16 It was also determined that HRG modulated macrophage protein synthesis and secretion that was directly associated with its regulation of macrophage FcR-dependent functions.
In this study, we provide evidence that HRG is capable of biphasically modulating complement functional efficiency, by either enhancement or inhibition, in both a time-and dose-dependent fashion. Serum complement C8, C9, factor D, and S-protein were found to bind to immobilized HRG, but in immunoprecipitation studies it was shown that HRG complexed only with S-protein in serum. Partial polymerization of C9 and generation of a C9 fragment were shown when purified C9 was treated with HRG. HRG also in serum. In functional tests, HRG inhibited C8 hemolytic activity, probably by preventing C8 binding to EAC1-7 cells. HRG also enhanced polymerization of purified C9 as well as the generation of a 45-Kd C9 fragment. Such an effect #as even more pronounced in the presence of divalent cations with the reaction mixtures of C9 and HRG. Partial dimerization of C9 was shown when exogenous HRG was added to normal serum. In contrast, polymerization of serum C9 was inhibited by exogenous HRG during poly I:C activation of serum or incubation under low ionic strength conditions. HRG was further shown to inhibit factor D-mediated cleavage of factor B when bound by cobra venom factor. The molecular basis by which HRG regulates serum complement function is not clear. Hypothetically, the tandem repetitions of a consensus histidine-rich penta-peptide sequence in HRG may provide a highly charged area that interach with complement components. o 1992 by The American Society of Hematology.
enhanced C9 dimerization when exogeneous HRG was added to serum. However, C9 polymerization was inhibited by HRG when activating serum complement in the presence of exogenous HRG. Thus, our in vitro studies suggest that HRG plays a significant role in modulating complement function.
man Ig antibodies were purchased from Sigma Chemicals (St Louis, MO).
Purification of HRG was performed according to our previously described procedures,16 which involved chromatographic steps of Cod-Sepharose 4B, heparin agarose, and diethyl aminoethyl (DEAEl)-Sephacel columns. The purified HRG migrated as a doublet of 58 and 64 Kd (glycoprotein [GP] 58, 64) in nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), but migrated up to 77 to 81 Kd under reducing conditions. When subjected to gas-phase microsequencing, the purified HRG has an NH-terminal sequence identical to the sequence deduced from cDNA. ' Titration of complement hemolytic activity by a kinetic method has been previously d e s~r i b e d . l~-~ Briefly, various quantities of HRG were incubated with prewarmed (37°C for 5 minutes) diluted human serum for 0 or 10 minutes at 3TC, followed by adding prewarmed EA cells (2 x lo7 cells/ml; sheep erythrocytes coated with hemolysin or antibodies against sheep red blood cells; Colorado Serum Co, Denver, CO). Hemolysis was continuously measured at 700 nm as a function of decreasing turbidity with time at 37°C using a 6-cuvette automatic kinetic spectrophotometer (Gilford Response; Ciba Corning Diagnostics Corp, Medfield, MA). The times to half-lysis ( t s ) of EA cells were measured and the percentages of hemolysis enhancement or inhibition by HRG as compared with controls were calculated according to a linearly regressed equation derived from a serially diluted human serum tested for hemolytic f~n c t i o n .~~-~ GVB, a gelatin-metal-Verona1 buffer, was the diluent of the assay s y~t e m . '~-~~ Complement alternative pathway was also tested by the kinetic method.21 Briefly, various quantities of HRG were incubated with equal volumes of diluted human serum at 37°C for 0 or 10 minutes before adding prewarmed rabbit erythrocytes (2 x lo7 cells/mL, suspended in EGTA-veronal-buffered saline [VBS] buffer2]). Time-dependent hemolysis was measured continuously in the 37°C kinetic spectrophotometer. Enhancement or inhibition oE complement alternative pathway activity by HRG versus controls was calculated as d e s~r i b e d . l~-~~ Purified HRG (1 mg) was covalently conjugated to CNBr-activated Sepharose 6MB beads according to the manufacturer's instructions (Sigma). Three milliliters of human serum was loaded onto the HRG-Sepharose 6MB column, which was preequilibrated with VBS,17-" followed by washing the column with 3-bed volumes of VBS. The HRGadsorbed serum was collected from the breakthrough fraction. Serum proteins bound by the HRG column were eluted using 1 mol/L NaCl-VBS buffer, followed by dialysis against VBS. Protein quantification was performed using the BioRad protein assay (BioRad Laboratories, Richmond, CA). The residual complement hemolytic activity of the HRG-adsorbed serum was measured by the kinetic methods. By comparison, identical quantities of unadsorbed or control sera were used for testing complement hemolytic functions. An average number of lesions per erythrocyte caused by effective complement molecules was calculated: z = -In (1 -y), where y is the degree of hemolysis and z is the average number of lesions per ce11. 22 Various quantities of HRG were immobilized onto a piece of zeta-probe nylon membrane (BioRad) using a 96-well Dot-Blot apparatus (BioRad). The membrane was incubated with 2% bovine serum albumin (Sigma) for 2 hours at 4°C to block nonspecific binding sites. One milliliter of 1:15 diluted human serum in 0.01 mol/L EDTA-VBS17-20.2Z was incubated with the membrane at 4°C for 30 minutes in an end-over-end shaker. After incubation, the membrane was washed twice with 0.1% NP-40 in Tris-buffered saline and recast onto the Dot-Blot apparatus for processing Western Purification of HRG.
Complement hemolytic assays.
Preparation of HRG-Sepharose 6MB column.
Binding of serum complement components to HRG.
blotting. 23 To each 4-well row, individual antibodies against each complement component diluted in 2% albumin were added and suctioned slowly by vacuum. The membrane was again washed twice with 0.1% NP-40, followed by incubation with 1251-labeled protein-A for detecting membrane-bound IgG.
To test whether HRG complexes with complement components in serum, serum HRG was immunoprecipitated by Sepharose 6MB beads conjugated with anti-HRG IgG. Four hundred microliters of human serum was mixed with 50 p,L of 50 mmol/L phenylmethylsulfonyl flouride (PMSF; Sigma), followed by preclearing with 100 p L ethanolamineinactivated CNBr-Sepharose 6 MB beads (Sigma) for 1 hour at 4°C by end-over-end rotating. For controls, no preclearing step was performed. Sepharose 6 MB beads conjugated with IgG against HRG were then added to the precleared or control human serum and incubated at 4°C for 3 hours by end-over-end rotating. The Sepharose 6 MB beads were then washed four timeswith phosphatebuffered saline (PBS) containing 0.1% NP-40 (Sigma) and 200 pmol/L PMSF, and heated at 100°C for 30 seconds in 100 pL of a 0.06 mol/L Tris HCl (pH 6.8) buffer containing 0.1% glycerol, 2.0% SDS, and 5% P-mercaptoethanol. Subsequent steps included SDS-PAGE, electroblotting, and Western blotting.u Antibodies used in Western blotting were anti-C8, C9, factor D, HRG, S-protein, and plasminogen, respectively. Demonstration of HRG and plasminogen complexes in serum is considered as a positive control? Similar immunoprecipitation experiments were performed using Sepharose 6MB beads coated with anti-S-protein IgG.
Purified human C9 (Quidel) was incubated with purified HRG at 37°C for 1.5 hours using the following buffers as diluents: (1) VBS; (2) VBS2+, VBS containing Ca2+ and Mg2+; (3) G V B and (4) EGTA-VBS buffer, VBS containing EGTA, gelatin, and Mg2+.17-22 Additionally, C9 was incubated with HRG at 37°C for various indicated times using 0.01 mol/L EDTA-VBS-gelatin buffer.17-" For controls, C9 or HRG alone was incubated identically using appropriate buffers. The reaction mixtures were separated in a 2.5% to 12.5% gradient SDS-PAGE under reducing or nonreducing conditions, followed by electroblotting onto pieces of hydrophobic PVDF-P membranes (Millipore, Bedford, MA). Western blotting was performed using polyclonal antibodies against human C9.' To test the effect of HRG on complement activation, serum was activated by poly I:C, or by incubation under low ionic strength conditions using DGVB2+ b~ffer,l~-~O in the presence or absence of HRG. Aliquots of the serum samples were analyzed by SDS-PAGE and Western blotting for C9.
Serum complement factor D was partially purified by using a Bio-Rex 70 column (Bio-Rad) 22 and the factor D-depleted serum (RD-serum) from the breakthrough fraction was collected. Hemolytic activity of the partially purified factor D was analyzed by adding to the mixtures of RD-serum and rabbit erythrocytes. Purified factor B (Quidel) was radioiodinated using lodo-Bead procedures (Pierce, Rockford, IL). Factor B (1 p,g) was then incubated with aliquots of partially purified factor D in the presence or absence of cobra venom factor (CoVF; 3.5 pg) and/or HRG (1 pg) for 1 hour at 37°C. Subsequent steps involved SDS-PAGE, gel drying, autoradiography, and scanning the X-ray film for analyzing factor D-mediated factor B conversion or fragmentation.
Immunoprecipitation and Western blotting.
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RESULTS
Biphasic modulation of complement hemolytic activity by HRG. Enhancement of complement-mediated hemolysis was obtained by mixing HRG with prewarmed diluted human serum (without prior incubation at 37°C) followed by the immediate addition of prewarmed EA cells to the mixtures (Fig 1A) . The hemolytic kinetics indicated that the extent of hemolysis enhancement was positively correlated with the quantity of exogenous HRG added to the diluted serum. However, a dose-dependent inhibition of complement hemolysis was obtained when HRG was incubated with diluted serum for 10 minutes at 37T, before adding prewarmed EA cells (Fig 1B) . Similar results were obtained when using other dilutions of human serum. Heatinactivated HRG (60°C for 30 minutes) was not capable of modulating complement function (data not shown).
Complement alternative pathway activity was also modulated by HRG when rabbit erythrocytes were used as target cells for. assay of complement hemolysis. Enhancement of complement hemolytic activity of the alternative pathway was obtained when HRG was mixed with prewarmed diluted human serum (without prior incubation) upon immediate addition of prewarmed rabbit erythrocytes (Fig  2) . Inhibition of complement alternative pathway activity occurred when HRG was incubated with diluted serum for 10 minutes at 37°C (data not shown).
HRGadsorbed serum was shown to have a reduced complement activity for both classical and alternative pathways in lysing EA cells as well as rabbit erythrocytes as compared with control serum (Fig 3A and B) . The reduced complement function in HRG-adsorbed serum could be restored by adding the eluted protein fractions bound by the HRGSepharose 6MB column (Fig 3C) . These results indicate that depletion of complement function in the HRGadsorbed serum was due to binding of serum complement components to immobilized HRG. To determine which complement components were bound by HRG, diluted human serum was incubated with an HRG-coated zetaprobe nylon membrane in the presence of EDTA. Complement C8, C9, D, and S-protein were bound by HRG as determined by Western blot analysis (Fig 4) .
Precipitation of HRG in relatively undiluted serum by anti-HRG IgG beads resulted in coprecipitation of HRG with S-protein of 65 and 75 Kd, but not with C8, C9, or factor D (Fig 5) . As a positive control, plasminogen was confirmed to also complex with HRG ( Fig   5) .6 Similarly, using anti-S-protein IgG beads for immunoprecipitation, HRG, but not C8, C9, or factor D, was found to complex with S-protein (data not shown). The use of serum that had been precleared with Sepharose 6 MB beads before immunoprecipitation made no significant difference in the results using nontreated control serum. Moreover, washing the anti-HRG or anti-S-protein IgGSepharose 6MB beads bound with target proteins in the presence or absence of 0.1% NP-40 made no difference in the results.
To assess the role of HRG on the regulation of the hemolytic activity of the late-acting complement components, HRG was incubated with C8 at 37°C for 0 and 15 minutes before the addition of C8-depleted serum and EA cells, followed by incubation at 37°C for 30 minutes. It was determined that C8 hemolytic activity was restricted by HRG (Table 1) .
When purified C9 was incubated with HRG in the presence of EDTA, HRG was shown to enhance partial C9 polymerization with increased time of incubation (Fig 6) . Besides partial C9 polymerization, a new C9 fragment of 45 Kd was observed when C9 reacted with HRG (Fig 6) . Although SDS-PAGE was performed under reducing conditions, there was no major difference in the protein pattern as compared with nonreducing conditions (data not shown). HRG-mediated C9 polymerization was even more pronounced, with 0.6-to 1.8-fold increases versus appropriate controls, when divalent cations were present in the buffer systems (VBS2+, GVB, or EGTA-buffer). Degradation of the commercially purified C9 was less than 2%.
Immunoprecipitation.
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When serum complement was activated by poly I:C, or by incubation under low ionic strength conditions,18 serum C9 was shown to be polymerized, which resulted in disappearance of C9 monomer (Fig 7) . However, HRG inhibited C9 polymerization in activated sera (Fig 7) . HRG alone, when directly mixed with human serum, was capable of inducing C9 dimerization (Fig 7) . Highly polymerized C9, eg, (C9),,. 12, was not shown in the Western blot, which was probably due to insufficient electro-transfer time and the high molecular weight nature of poly (C9) that made the electro-transfer more difficult.
CoVFbound factor B was cleaved by the partially purified factor D ( Table 2 ). Factor B fragmentation was shown to be inhibited by HRG (Table 2) 
DISCUSSION
HRG is a single-chain polypeptide with an apparent molecular weight of 75 Kd.1,24925 Its functional role in the complement system has never been documented. One of the striking characteristics of HRG is its unusually high content of histidine and proline, each of which exceeds 12% of the total amino acid content of the protein.lS6 Molecular cloning studies show that HRG possesses 12 tandem repetitions of 5 amino acid segment with a consensus sequence of Gly-His-His-Pro-His.l Probably due to such a unique molecular architecture, HRG is capable of interacting with charged molecules such as heparin and divalent cations. 24 The functional significance of reduction of HRG levels during the acute-phase response is unknown. Hypothetically, under physiologic conditions HRG may play a "housekeeping" role in regulating blood components and Complex formation between HRG and S-protein in serum. Four hundred microliters of undiluted serum was precleared with (E) or without (A) Sepharose 6MB beads, in the presence of 5.6 mmol/L PMSF, followed by adding 100 FL anti-HRG IgGSepharose 6MB beads and incubating at 4°C for 2 hours in an end-over-end rotator. The beads were then washed with 0.1% NP-40 in PBS four times. Subsequent steps included SDS-PAGE, electroblotting, Western blotting, and autoradiography. The immunoprecipitates contained HRG (78 Kd) along with S-protein (65 and 75 Kd) and plasminogen (90 Kd), but not with C8, C9, and factor D, as determined by respective antibodies. The arrowhead indicates the released IgG heavy chain from beads after heating at 100°C. Also, the IgG light chain against HRG migrated t o a 22-Kd position. HRG (500 ng) was incubated with 20 U of C8 at 37°C for 0 or 15 minutes before adding 4 pL of C8-depleted human serum (Quidel) and 100 pL of antibody-coated EA (5 x 107 cells) with a further 30 minutes of incubation at 37°C. The final volume was adjusted to 700 pL using GBV buffer, VBS containing 0.1% gelatin, 1.0 mmol/L Mg*+, and 0.15 mmol/L CaCI2. The absence of HRG in the reaction mixtures was regarded as the controls. Purified C9 (1 pg) was incubated with HRG (1 pg) for 30 to 240 minutes at 37°C using 0.01 mol/L EDTA-VBS-gelatin buffer. Electrophoresis was performed in a 2.5% to 12.5% SDS-PAGE under reducing conditions, followed by electroblotting, Western blotting, and quantification by X-ray film scanning. HRG caused C9 fragmentation, resulting in a unique 45-Kd C9 fragment (see arrowhead). Untreated C9 control with less than 2% degradation is indicated by an arrow (the first left lane). Controls (-): C9; experiments (+): C9 and HRG. The extent of C9 polymerization was determined by extrapolation from the regressed line of the molecular weight standard. C9 dimer, trimer, tetramer, and pentamer are presented by "2+", "3+", and so on. Radioiodinated complement factor B (1 pg) was incubated with partial purified factor D in the presence or absence of CoVF (3.5 pg) and/or HRG (1 pg) at 37°C for 1 hour. After SDS-PAGE and autoradiography, percentages of factor B conversion were quantified by scanning the X-ray film.
tion during serum complement activation by poly I:C or by incubation under low ionic strength conditions. Furthermore, HRG is capable of restricting factor D-mediated cleavage of CoVF-bound factor B. Overall, HRG's regulatory activity for each tested complement component strongly suggests that HRG binds directly to these complement components under experimental conditions.
A balanced concentration of HRG in serum must be of physiologic significance. For instance, when exogenous HRG was added to serum, partial dimerization of serum C9 resulted. In hemolytic assays, the exogenous HRG appears to cause a time-dependent shift of chemical balance of the complement system, thereby either enhancing or inhibiting complement function. The enhancing phase may represent a transient period of accelerating C9 polymeration by HRG. However, upon longer incubation with diluted serum, serum C8 may be restricted by HRG and excessive fluid-phase C9 polymerization probably occurred, thus reducing the complement hemolytic activity.
The complement membrane-attack complex (MAC) is composed of complement C5b, C6, C7, C8, and C9 and can be assembled in two ways.27-29 Upon activation of the complement cascade on a phospholipid membrane, the assembly of MAC becomes amphiphilic upon acquisition of C7 to C5b-6, and eventually a transmembrane channel is formed by the polymerization of C9.30-32 Alternatively, MAC can be generated in the fluid phase by the activation of serum. In this case, serum S-protein and SP-40,40 are additional components to the MAC (SC5b-9).32-37 In our studies, HRG was found to complex with S-protein in serum. An intriguing question is how both molecules cooperate to restrict or enhance C9 polymerization. Although HRG has never been shown in MAC, HRG must be able to regulate the formation of SC5b-9 complex in the fluid phase. Possible regulatory mechanisms are: (1) HRG may act as a cofactor for S-protein in preventing serum C9 polymerization, because serum S-protein is believed to inhibit C9 polymerization and render the SC5b-9 complex more h y d r o p h i l i~~~-~~; or (2) the functional activity of S-protein may be neutralized by HRG, thereby facilitating C9 polymerization on cell membrane; or (3) HRG may modulate the function of serum SP-40,40 in binding to SC5b-9. SP-40,40 is a serum protein that has been reported to complex with fluid-phase-generated SC5b-9, but not to the membrane-bound C5b-9.36 Like the function of S-protein, SP-40,40 inhibits C5b-&initiated complement hemolysis. 37 Hydropathy analysis shows that HRG is a hydrophilic molecule, and, particularly, its histidine-rich region (residues 330-389) is highly hydrophilic.' The predicted secondary structure of the histidine-rich region contains no helics, but consists of p-turn and random coil.' These results indicate that the histidine-rich region is most likely surfaceexposed and readily accessible for interaction with other molecules. One study reported that the binding site for heme is located within the histidine-rich region.38 Conceivably, the histidine-rich region in HRG also could interact with complement components. HRG alone may interact with C9 via the highly charged histidine-rich region, thereby increasing C9-C9 contact for further polymerization. Although HRG is not a protease, it is intriguing to find that HRG causes C9 fragmentation. Such fragmentation probably occurs as a result of charge interactions that destabilize C9 molecules. It has been reported that HRG belongs to a cystatin s~perfamily.~~ Whether HRG binds to the cysteinerich regions of C8 and C9 is unknown. Nonetheless, both the susceptible site of C9 for HRG binding and the cleavage site in C9 remain to be established.
Homologous restriction factors are membrane-associated proteins capable of blocking homologous complementmediated lysis. These include a 65-Kd C8 binding prot e i n @~~~ and a 20-Kd homologous restriction factor (HRF20 or CD59).42,43 HRG is distinct from both proteins and regulates complement function in the fluid phase, whereas homologous restriction factors control complement function at the membrane level. The 65-Kd C8 binding protein is homologous to C8, C9, and perforin through cysteine-rich domain^.^^.^ Whether HRG binds to the membrane 65-Kd C8 binding protein remains to be determined.
Regulation of factor D function by a specific serum protease inhibitor(s) has never been reported. Although it was found that the electrophoretic mobility of factor D in agarose gels could be shifted by a serum component, functional regulation of factor D by this serum component is not clear. 45 Other in vitro studies showed that antithrombin I11 may inhibit factor D function.46 HRG is obviously not a specific protease inhibitor for factor D, whereas the restriction of factor D activity by HRG, probably via ionic interactions, may play a significant role in controlling the efficiency of complement alternative pathway in vivo.
Taken together, in this study we report that regulation of complement function by HRG is via interactions with C8, C9, factor D, and S-protein of the complement pathways. Thus, changes in serum HRG levels during diseased states may not only alter the efficiency of fibrinolysis, but also affect the functional capacity of complement system.
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